Literature DB >> 292801

Persistence of infectious Friend virus in spleens of mice after spontaneous recovery from virus-induced erythroleukemia.

B Chesebro, M Bloom, K Wehrly, J Nishio.   

Abstract

Persistent infectious virus was detected in the majority of spleens of (C57BL/10 X A.BY)F1 mice after spontaneous recovery from Friend virus-induced erythroleukeima. The Friend murine leukemia helper virus (F-MuLV) was detected in titers up to 3 X 10(5) PFU/g of spleen. The defective spleen focus-forming virus (SFFV) was present in much lower titers and could be detected in cell-free spleen homogenates only after amplification of virus titer by growth of virus in vitro on SC1 cells. The incidence of cells producing F-MuLV alone in spleens after recovery from leukemia was 0.003 to 0.3%, and the incidence of cells producing both F-MuLV and SFFV was less than 0.0001 to 0.01%. In most recovered mouse spleens there appeared to be a selective reduction of SFFV relative to F-MuLV.

Entities:  

Mesh:

Year:  1979        PMID: 292801      PMCID: PMC525931     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Rapid cell culture assay technic for murine leukaemia viruses.

Authors:  R H Bassin; N Tuttle; P J Fischinger
Journal:  Nature       Date:  1971-02-19       Impact factor: 49.962

2.  Suppression of established Friend virus leukemia by statolon. IV. Role of humoral antibody in the development of a dormant infection.

Authors:  E F Wheelock; S T Toy; N L Caroline; L R Sibal; M A Fink; P C Beverley; A C Allison
Journal:  J Natl Cancer Inst       Date:  1972-03       Impact factor: 13.506

3.  Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice.

Authors:  F Lilly
Journal:  J Natl Cancer Inst       Date:  1970-07       Impact factor: 13.506

4.  Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody.

Authors:  E A Boyse; E Stockert; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

5.  B-tropic Friend virus: a host-range pseudotype of spleen focus-forming virus (SFFV).

Authors:  F Lilly; R A Steeves
Journal:  Virology       Date:  1973-10       Impact factor: 3.616

6.  Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity.

Authors:  B Chesebro; K Wehrly
Journal:  J Exp Med       Date:  1976-01-01       Impact factor: 14.307

7.  Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation.

Authors:  B S Joseph; M B Oldstone
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

8.  Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies.

Authors:  B Chesebro; K Wehrly
Journal:  J Exp Med       Date:  1976-01-01       Impact factor: 14.307

9.  Continuous replication of Friend virus complex (spleen focus-forming virus-lymphatic leukemia-inducing virus) in mouse embryo fibroblasts. Retention of leukemogenicity and loss of immunosuppressive properties.

Authors:  R J Eckner
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

10.  Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex.

Authors:  B Chesebro; K Wehrly; J Stimpfling
Journal:  J Exp Med       Date:  1974-12-01       Impact factor: 14.307

View more
  17 in total

1.  CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.

Authors:  Gennadiy Zelinskyy; Shelly J Robertson; Simone Schimmer; Ronald J Messer; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Robert S Mittler; Christopher Burlak; Kim J Hasenkrug
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

Review 3.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  Replication-defective Friend murine leukemia virus particles containing uncleaved gag polyproteins and decreased levels of envelope glycoprotein.

Authors:  J K Collins; B Chesebro
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

5.  Differing T-cell requirements for recombinant retrovirus vaccines.

Authors:  K J Hasenkrug; D M Brooks; J Nishio; B Chesebro
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Protection against establishment of retroviral persistence by vaccination with a live attenuated virus.

Authors:  U Dittmer; D M Brooks; K J Hasenkrug
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection.

Authors:  M Iwashiro; R J Messer; K E Peterson; I M Stromnes; T Sugie; K J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

8.  CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection.

Authors:  M Iwashiro; K Peterson; R J Messer; I M Stromnes; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  Characterization of chimeric full-length molecular clones of Aleutian mink disease parvovirus (ADV): identification of a determinant governing replication of ADV in cell culture.

Authors:  M E Bloom; B D Berry; W Wei; S Perryman; J B Wolfinbarger
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.

Authors:  U Dittmer; D M Brooks; K J Hasenkrug
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.